ClinicalTrials.gg
CompletedNCT00830128Updated Jan 25, 2021Results posted

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia

A Phase 3 interventional study of pregabalin (Lyrica) in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
22nd of 30
106 · median 199
Started
2009
with 2 others
Phase 3
13 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 22nd largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 9th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081208, and must have received pregabalin/placebo under double-blind conditions.

Exclusion criteria

Exclusion Criteria:

  • Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081208; which was determined to be related to the study medication by the investigator or the sponsor.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    pregabalin (Lyrica)

    Drug: pregabalin (Lyrica)

Interventions

  • Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; lifethreatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.

    Time frame: Up to 53 weeks

Secondary outcomes

  1. Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint

    The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  2. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep disturbance. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  3. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  4. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  5. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep adequacy. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  6. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score means greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  7. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  8. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint

    MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  9. Medical Outcomes Study (MOS) Sleep Scale - Optimal Sleep at Endpoint

    MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Number of participants with response = YES if sleep quantity is 7 or 8 hours per night or response = NO if sleep quantity is \< 7 hours per night.

    Time frame: Week 52 or Study Discontinuation

  10. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

  11. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Subscale Score at Endpoint

    FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

    Time frame: Baseline, Week 52 or Study Discontinuation

07

Results

Posted Feb 14, 2012

Participant flow

Participant flow — Overall Study
MilestonePregabalin
Started106
Completed87
Not completed19
Withdrew: Adverse event5
Withdrew: Lack of efficacy7
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject2
Withdrew: Family obligation1
Withdrew: Relocation1
Withdrew: Work obligation1
Withdrew: Operating a vehicle1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; lifethreatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.

Time frame:
Up to 53 weeks
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPregabalin
All-causality adverse events (AEs)102
All-causality SAEs3
SecondaryChange From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint

The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · mm
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint
mmPregabalin
Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint-13.1 ± 25.3
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep disturbance. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint-9.6 ± 23.3
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint1.9 ± 22.3
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint-3.0 ± 23.1
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep adequacy. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint4.2 ± 21.3
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score means greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · hours
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint
hoursPregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint0.3 ± 1.2
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint7.2 ± 24.0
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint

MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms. Change = mean scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint
Units on a scalePregabalin
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint-3.7 ± 15.7
SecondaryMedical Outcomes Study (MOS) Sleep Scale - Optimal Sleep at Endpoint

MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Number of participants with response = YES if sleep quantity is 7 or 8 hours per night or response = NO if sleep quantity is \< 7 hours per night.

Time frame:
Week 52 or Study Discontinuation
Reported as:
Number · Paticipants
Medical Outcomes Study (MOS) Sleep Scale - Optimal Sleep at Endpoint
PaticipantsPregabalin
Yes26
No80
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint
Units on a scalePregabalin
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint-4.9 ± 17.2
SecondaryChange From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Subscale Score at Endpoint

FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.

Time frame:
Baseline, Week 52 or Study Discontinuation
Reported as:
Mean · Units on a scale
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Subscale Score at Endpoint
Units on a scalePregabalin
Physical Functioning-0.2 ± 2.0
Feel Good-0.4 ± 2.7
Work Missed-0.5 ± 2.8
Difficulty Working-0.7 ± 2.6
Pain-1.0 ± 2.3
Fatigue-0.3 ± 1.9
Morning Tiredness-0.6 ± 2.2
Stiffness-0.7 ± 2.5
Anoxiouness-0.3 ± 2.6
Depression-0.2 ± 2.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—3/106 (2.8%)92/106 (86.8%)
Most frequent serious events
Most frequent serious events
EventPregabalin
TuberculosisInfections and infestations1/106
Crush InjuryInjury, poisoning and procedural complications1/106
Compartment SyndromeMusculoskeletal and connective tissue disorders1/106
Neuropathy PeripheralNervous system disorders1/106
Nasal Septum DeviationRespiratory, thoracic and mediastinal disorders1/106
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPregabalin
NasopharyngitisInfections and infestations33/106
SomnolenceNervous system disorders31/106
DizzinessNervous system disorders28/106
ConstipationGastrointestinal disorders23/106
Weight increasedInvestigations21/106
HeadacheNervous system disorders12/106
Oedema peripheralGeneral disorders9/106
FibromyalgiaMusculoskeletal and connective tissue disorders9/106
Abdominal pain upperGastrointestinal disorders8/106
OsteoarthritisMusculoskeletal and connective tissue disorders8/106

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pregabalin
<18 years0
Between 18 and 44 years47
Between 45 and 64 years49
>= 65 years10
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female89
Male17
08

Study locations

20 sites
  • Pfizer Investigational Site
    Yotukaidou, Chiba, Japan
  • Pfizer Investigational Site
    Matuyama-si, Ehime, Japan
  • Pfizer Investigational Site
    Iiduka, Fukuoka, Japan
  • Pfizer Investigational Site
    Kobe, Hyogo, Japan
  • Pfizer Investigational Site
    Kobe, Hyougo, Japan
  • Pfizer Investigational Site
    Mito, Ibaraki, Japan
  • Pfizer Investigational Site
    Morioka, Iwate, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Tsu, Mie, Japan
  • Pfizer Investigational Site
    Sendai, Miyagi, Japan
  • Pfizer Investigational Site
    Hiki-gun, Saitama, Japan
  • Pfizer Investigational Site
    Saitama-shi, Saitama, Japan
  • Pfizer Investigational Site
    Shimotsuga-gun, Tochigi, Japan
  • Pfizer Investigational Site
    Chiyoda-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Itabashi-Ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shinagawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Nagano, Japan
  • Pfizer Investigational Site
    Oita, Japan
  • Pfizer Investigational Site
    Osaka, Japan
  • Pfizer Investigational Site
    Yokohama, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 27, 2009
Start
Jul 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Feb 14, 2012
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00830128
Responsible party
Sponsor
First posted
Jan 27, 2009
Start date
Jul 2009
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Feb 14, 2012
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion